SERVIER
Of approximately 10,000 initial ideas that begin the development process, 9,999 fail to reach patients due to scientific, regulatory or commercial obstacles. This failure rate creates pressure for pharmaceutical companies to identify promising compounds early in the development cycle. Servier applies technology throughout its value chain to accelerate processes and support decision-making. The company uses data analytics and AI to reduce the initial pool of ideas more efficiently before conducting detailed investigations.
Machine learning algorithms can analyse molecular structures, predict compound behaviour and identify potential safety issues before expensive clinical trials begin. This approach helps pharmaceutical companies allocate resources more effectively and reduce development timelines.
SERVIER PHARMACEUTICALS: A GLOBAL LEADER DRIVEN BY THERAPEUTIC PROGRESS
Servier Pharmaceuticals is a French multinational pharmaceutical company headquartered in Suresnes, France. Founded in 1954 by Jacques Servier, the company is a global healthcare leader, operating in 150 countries with a dedicated workforce of over 21,000 employees. Servier is governed by a non-profit foundation, which allows it to maintain a long-term vision and reinvest a significant portion of its revenue back into research and development.
The oncology-focused group operates across discovery, development, manufacturing and patient services. Each function generates and consumes data that feeds into the company’ s technology infrastructure, creating opportunities for cross-functional insights and process optimisation.
Claritas Rx partnership consolidates Servier data sources across operations Servier partners with data aggregator Claritas Rx to manage complex data requirements across its pharmaceutical operations. This relationship originated through Servier’ s acquisition of the oncology portfolio from Agios Pharmaceuticals, demonstrating how mergers and acquisitions can introduce new technology partnerships.
Claritas Rx functions as a data aggregation platform that consolidates information from multiple sources including thirdparty logistics providers, clinical research organisations and regulatory databases. This consolidation creates a unified data ecosystem that supports analysis across different business functions.
The pharmaceutical industry generates data from clinical trials, manufacturing processes, regulatory submissions, sales activities and patient interactions. Managing these disparate data sources requires sophisticated aggregation and analysis capabilities.
Taking a consolidated approach enables Servier to analyse information from multiple sources within a unified framework. This integration supports data-driven decisionmaking across research, development, manufacturing and commercial activities.
82 December 2025